Oncogenic NRAS required CRAF to activate the MEK/ERK pathway.

<p>A, SK-MEL-2 cells were transfected with siRNAs for the negative control (N), BRAF (B), or CRAF (C), and without siRNAs for mock (M). After the indicated times, cell extracts were analysed by immunoblotting for the indicated proteins. B, SK-MEL-2 cells were transfected with siRNA for the negative control (N), BRAF (B), and CRAF (C) , and without siRNAs for mock (M). After 24 h, 100 nM of CH5126766 or 10 nM of PD0325901 were added to the cells. The cells were harvested for immunoblot analysis after 24 h. CH; CH5126766, PD; PD0325901